Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Supporting Treatment Adherence Readiness Through Training (START) (START)

5. oktober 2020 opdateret af: RAND

Controlled Evaluation of the Adherence Readiness Program for ART Adherence

Multi-site, randomized controlled trial of the Adherence Readiness Program (ARP) adherence intervention for HIV clients starting or restarting antiretroviral therapy (ART) for the purpose of achieving and sustaining optimal levels of ART adherence and virologic suppression. Eligible participants will be randomized to receive either the ARP intervention or usual care (no intervention) and followed for 24 months.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This study will evaluate the effects of the Adherence Readiness Program (ARP) intervention on the primary outcomes of dose-taking HIV antiretroviral (ART) adherence and undetectable HIV viral load in a multi-site randomized controlled trial. The ARP is based on the Information Motivation Behavioral skills (IMB) model of behavior change and includes (1) brief pill taking practice trials for enhancing pre-treatment adherence counseling and providing a behavioral criterion for determining adherence readiness and the start of treatment, and (2) a performance driven dose regulation mechanism to tailor the amount of counseling (from pre-treatment through the full course of treatment) to the individual needs of the patient and conserve limited resources. Participants will be randomized to receive either the ARP (adherence counseling sessions) or usual care. Primary assessments will be administered at screening and every 6 months after ART initiation over a 24-month follow-up, making it one of the few studies to examine intervention effects longer than one year. Secondary outcomes include dose-timing adherence and CD4 count. If effective, the ARP will provide clinicians with an intervention that (1) informs providers and patients when the patient is ready to adhere well and start treatment, (2) enhances adherence readiness from the outset of treatment through the full course of therapy, and (3) tailors the amount of adherence support based on individual patient need and performance, thus more efficiently using clinic resources, fostering better acceptance from providers and patients, and increasing the likelihood of successful program adoption and dissemination. This emphasis on efficient use of resources will be complemented by a cost-effectiveness analysis to further inform policy decisions regarding the transportability of the intervention and its potential for more wide scale use and sustainability if effective.

Undersøgelsestype

Interventionel

Tilmelding (Forventet)

240

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • California
      • Long Beach, California, Forenede Stater
        • Care Clinic
      • Los Angeles, California, Forenede Stater
        • T.H.E. Clinic
      • Los Angeles, California, Forenede Stater
        • UCLA CARE Center

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  1. The patient's provider views the patient as medically appropriate to begin (ART naïve) or restart ART (has been off ART for at least 2 months), and either

    • plans to start the patient on ART
    • would like to start the patient on ART but the provider or patient is uncertain about the patient's readiness to adhere well.

    Patients who are currently on ART are also eligible if they meet the following criteria, which are specific only to this type of patient:

    i) the patient has 2 or more HIV viral load tests in the past year > 1000 copies/ml ii) the patient has had no HIV viral load tests that were undetectable in the past year iii) the patient has a genotype in the past year that does not show resistance as a reason for virologic failure (detectable viral load) iv) primary care provider views the patient as a good candidate for the study, with the understanding that the patient will interrupt ART if assigned to the intervention.

    Criteria i to iii are intended to define a subgroup of nonadherent patients who are taking very little of their ART medications, as evidenced by the combination of consistently high viral load and no drug resistance. If the patient was taking at least a moderate level of drug and still had consistently high viral load, than they would have evidence of drug resistance. Providers are generally comfortable with this type of patient stopping their medication in order to facilitate the pre-treatment, adherence readiness assessment and training phase of the intervention prior to restarting the patient on treatment.

  2. The patient's health status is stable. There is no current acute OI or medical condition that calls for immediate ART, as determined by the patient's provider.
  3. Most recent HIV viral load is detectable.
  4. If CD4 < 200, the patient is on or will be prescribed prophylactic medication
  5. Patient is 18 or older.
  6. Patient is able and willing to give informed consent.
  7. English speaking.

Exclusion Criteria:

1. Patient just tested HIV+ and their provider suspects the patient may be acutely or recently infected (within past 6 months).

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ARP intervention
Adherence counseling intervention
Adfærdsmæssigt: Adherence Readiness Program
The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
Ingen indgriben: usual care
no intervention, standard care practices regarding adherence support

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
HIV virologic suppression
Tidsramme: Month 24
undetectable HIV viral load at time of assessment
Month 24
log change in HIV viral load (log change in HIV RNA levels)
Tidsramme: Month 24
log change in HIV RNA levels from baseline to Month 24.
Month 24
optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)
Tidsramme: Month 24
binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 24
Month 24
percent dose-taking adherence
Tidsramme: Month 24
percent of prescribed doses taken between baseline and Month 24
Month 24
HIV virologic suppression
Tidsramme: Month 6
undetectable HIV viral load at time of assessment
Month 6
log change in HIV viral load (log change in HIV RNA levels)
Tidsramme: Month 6
log change in HIV RNA levels from baseline to Month 6
Month 6
optimal dose-taking adherence (whether at least 85% of prescribed doses were taken)
Tidsramme: month 6
binary variable representing whether at least 85% of prescribed doses were taken between baseline and Month 6
month 6
percent dose-taking adherence
Tidsramme: month 6
percent of prescribed doses taken between baseline and Month 6
month 6

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
dose-timing adherence
Tidsramme: Month 24
percent of prescribed doses taken within correct time-window between baseline and Month 24
Month 24
dose-timing adherence
Tidsramme: Month 6
percent of prescribed doses taken within correct time-window between baseline and Month 6
Month 6
optimal dose-timing adherence
Tidsramme: Month 24
binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 24
Month 24
optimal dose-timing adherence
Tidsramme: Month 6
binary variable representing whether at least 85% of prescribed doses were taken within correct time-window between baseline and Month 6
Month 6
change in CD4 count
Tidsramme: Month 24
change in CD4 count from baseline to Month 24
Month 24
change in CD4 count
Tidsramme: Month 6
change in CD4 count from baseline to Month 6
Month 6
clinic attendance (number of missed clinic appointments)
Tidsramme: Month 24
number of missed clinic appointments between baseline and Month 24
Month 24
clinic attendance (number of missed clinic appointments)
Tidsramme: Month 6
number of missed clinic appointments between baseline and Month 6
Month 6

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

RAND

Samarbejdspartnere

University of California, Los Angeles
Long Beach Education and Research Consultants

Efterforskere

  • Ledende efterforsker: Glenn Wagner, PhD, RAND

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Generelle publikationer

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

1. februar 2015

Primær færdiggørelse (Faktiske)

30. marts 2020

Studieafslutning (Faktiske)

30. marts 2020

Datoer for studieregistrering

Først indsendt

22. december 2014

Først indsendt, der opfyldte QC-kriterier

31. december 2014

Først opslået (Skøn)

1. januar 2015

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

6. oktober 2020

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

5. oktober 2020

Sidst verificeret

1. oktober 2020

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • MH104086

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV Medication Adherence

Kliniske forsøg med Adherence Readiness Program

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Burkina Faso

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner